Podcast: New Therapeutic Agents for Difficult to Treat Autoimmune Diseases

A conversation between Karen Jagoda of Empowered Patient Podcasts and Dr. Dolca Thomas, Executive VP Research & Development of Equillium


Equillium, targeting autoimmune diseases where patients do not have a medicine that can lead to complete remission. In development, is the drug itolizumab considered a first-in-class, that focuses on the specific target and impacts what is known in the immune response as costimulation. Dolca elaborates, "Right now, at Equillium, we're focusing on three difficult to treat autoimmune diseases. The first is graft-versus-host disease. This is a condition that develops in patients after they've had a bone marrow transplant where the donor cells that are used to treat the malignancy, the cancer that the patient has, then, later on, starts to attack the cells that belong to the patient. This is a disease that can occur anytime from immediately after transplant up to 100 days post-transplant."


Listen to the podcast  Download the podcast transcript


Medical and Pharma Insider website